Want to see TSE:LCR full AI Analyst Report?
LCR Stock Chart & Stats
C$0.02
>-C$0.01(-20.00%)
At close: 4:00 PM EDT
C$0.02
>-C$0.01(-20.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.07
Previous CloseN/A
Volume8.00K
Average Volume (3M)290.69K
Market Cap
C$2.18M
Enterprise ValueC$5.27
Total Cash (Recent Filing)C$33.82K
Total Debt (Recent Filing)C$1.10M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Nov 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding108,819,870
10 Day Avg. Volume583,757
30 Day Avg. Volume290,695
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)-9.40
Price to Sales (P/S)0.00
P/FCF Ratio-6.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early-stage Therapeutic And Intellectual-property PlatformThe company retains a focused biotechnology R&D platform rather than operating across unrelated activities. Progress in psychedelic therapeutics or IP could create strategic value, although commercialization and clinical validation remain unproven.
Reduced Losses Versus The Exceptionally Weak 2021 ResultLower losses than the exceptionally weak 2021 result suggest some improvement in cost control or operating discipline. This provides a limited foundation for future efficiency, but has not yet translated into recurring revenue or profitability.
Moderate Absolute Debt BurdenModerate absolute debt can reduce fixed financing pressure compared with a heavily leveraged balance sheet and may preserve some strategic flexibility. However, the benefit is constrained by negative equity and the company’s reliance on external funding.
Bears Say
No Stable Revenue BaseThe absence of recurring revenue leaves the business dependent on financing, asset monetization, or future development success. It also prevents operating leverage and makes the company’s long-term economics difficult to validate.
Persistent Operating And Net LossesContinuing operating and net losses indicate that the current business model has not reached commercial viability. Without revenue growth or materially lower costs, ongoing losses can consume resources and increase dependence on additional capital.
Negative Equity And Continued Cash BurnNegative equity weakens financial resilience, while sustained operating cash outflows require external funding to maintain operations. Together, these conditions raise solvency, dilution, and execution risks over the medium term.
NeonMind Biosciences Inc News
LCR FAQ
What was NeonMind Biosciences Inc’s price range in the past 12 months?
NeonMind Biosciences Inc lowest stock price was C$0.01 and its highest was C$0.07 in the past 12 months.
What is NeonMind Biosciences Inc’s market cap?
NeonMind Biosciences Inc’s market cap is C$2.18M.
When is NeonMind Biosciences Inc’s upcoming earnings report date?
NeonMind Biosciences Inc’s upcoming earnings report date is Nov 27, 2026 which is in 91 days.
How were NeonMind Biosciences Inc’s earnings last quarter?
Currently, no data Available
Is NeonMind Biosciences Inc overvalued?
According to Wall Street analysts NeonMind Biosciences Inc’s price is currently Overvalued.
Does NeonMind Biosciences Inc pay dividends?
NeonMind Biosciences Inc does not currently pay dividends.
What is NeonMind Biosciences Inc’s EPS estimate?
NeonMind Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NeonMind Biosciences Inc have?
NeonMind Biosciences Inc has 108,819,870 shares outstanding.
What happened to NeonMind Biosciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeonMind Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:LCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NeonMind Biosciences Inc
Lancaster Resources Inc. focuses on acquiring, exploring, and advancing both mineral deposits and sustainable energy initiatives. A notable asset for the company is its exclusive right to acquire full ownership of the Alkali Flat lithium brine project, located in Lordsburg, New Mexico, in the United States. The firm's headquarters are situated in West Vancouver, Canada.